Raymond C. Dabney - President & CEO, Co-Founder and Director
Mr. Raymond C. Dabney, President & CEO, brings 25 years of experience in corporate finance, corporate structure, corporate communications, sales and marketing for public companies. Mr. Dabney has significant experience in public and private venture capital, early stage equity/debt financings and regulatory compliance.
Mr. Dabney has co-founded several public and private companies in many diverse industries such as drug development, entertainment, media, advertising, mining, automobile, high-tech, manufacturing, real estate and communications, many of which he launched from day one. Cannabis Science is a prime example of the type of organizations that Mr. Dabney has built from inception. Mr. Dabney has extensive international relationships that he has utilized to grow each Company, from the US, Canada, several European centers, such as Paris, London, Amsterdam and eastern Spain, as well as countries in the West Indies, South America, and Asia. Mr. Dabney’s niche market knowledge, team leadership, and management style facilitate the continued growth and forward thinking that successfully bring his projects from concept to completion.
Allen A. Herman, M.B., Ch.B., Ph.D. - Chief Medical Officer
Dr. Allen Herman is an epidemiologist and public health physician. He was the founding Dean of the National School of Public Health, Medical University of Southern Africa of the Republic of South Africa. He graduated in Medicine from the University of Natal in 1977 and completed his doctoral work in Epidemiology at the University of the Witwatersrand in 1989. He was a postdoctoral fellow in Epidemiology at Columbia University in New York in 1986 and a member of the faculty from 1987 to 1988. From 1989 to 1997 he was a Visiting Scientist at the National Institutes of Health. He was an Adjunct Professor at the George Washington University School of Public Health and Health Services from 1997 to 2004. Dr. Herman has extensive experience in developing and managing epidemiologic and public health research projects, and he is adept at secondary data analysis. In 1990 he helped develop the Baltimore Project, an Infant Mortality Reduction Initiative in Baltimore, Maryland. This community-based, model enriched prenatal care demonstration project for East Baltimore formed part of the basis for a $160 million dollar federally funded national program to reduce infant mortality. In 1992 he developed the scientific basis of the National Institutes of Health - District of Columbia Infant Mortality Reduction Initiative. He was the scientific director of this $25 million community-based U.S. federal research project that was designed to identify the critical factors that contribute to a high infant mortality among poor inner city African Americans and to develop interventions to reduce infant mortality rates.
In 1990 he was a member of the steering committee of a consortium of research programs for maternally-linked data from: the National Institutes of Health, the Centers for Disease Control and Prevention, the University of Oxford, the Australian Institute of Child Health, the Israeli Central Bureau of Statistics, and the University of Bergen, Norway. Maternally-linked data were created for several million births by linking birth data of siblings from the same mother into sibships. In the absence of national identification numbers that would allow deterministic linkage of birth records, Dr. Herman and his colleagues developed probabilistic linkage algorithms to create sibships for the states of Georgia, Washington, Missouri, and Utah. The work of the consortium culminated in an International Symposium on Maternally Linked Pregnancy Outcomes held in September 1995 in Atlanta, GA and a special issue of the journal Paediatric and Perinatal Epidemiology edited by Melissa Adams of the CDC, Allen Herman, and Francis Notzen of the National Center for Health Statistics.
From 2008 to 2013 Dr. Herman worked in Tennessee and Mississippi developing and implementing community oriented primary care based diabetes self management education (DSME) programs. He worked with federally qualified health centers (FQHCs) and private sector primary care providers to DSME to underserved communities in western Tennessee and Mississippi. These were among the initial Every One with Diabetes Counts programs of the Centers for Medicare and Medicaid Services and established the effectiveness of group based DSME interventions for Medicare beneficiaries.
Benjamin C.K. Tam - CFO and Director
Benjamin C.K. Tam was a contract controller for a chain of grocery stores since May 2013. Previously he served as chief financial officer of Ever88 Entertainment N.V. from 2010 to 2013, chief financial officer of CGTV Games Limited from 2006 to 2010, chief financial officer of Digifonica Canada Limited and Molaris Corp. from 2005 to 2006, public accountant and consultant from 1996 to 2005, chief financial officer/chief executive officer and director of Darius Technology Ltd from 1987 to 1996, and vice-president of finance and director of Bulldog Bag Ltd from 1978 to 1987.
Benjamin has been assisting the filing of financial reports of Cannabis Science since December 2015. He is a member of Chartered Professional Accountants (CPA) / Certified General Accountant (CGA) and obtained his CGA through University of British Columbia. He also holds a diploma of Business Administration from Lethbridge Community College, Alberta.
Mario Lap - President of European Operations and Director
Mr. Lap brings to the Company a unique combination of expertise in Dutch and greater European medical cannabis law and policy as well as in the areas of health care, IT security, law enforcement, and government relations. Mr. Lap has written numerous international papers and legislative initiatives regarding medical and non-medicinal cannabis laws and access throughout Europe. Mr. Lap has made several television and radio appearances on CNN, BBC, France 2, RTL, and various Dutch public and commercial channels to give public education and information on policy, laws, and current medical breakthroughs.
Mr. Lap, a Dutch health and IT regulatory lawyer in Amsterdam, has extensive experience in Europe with health care and drug policy, medical cannabis regulation, substance use policy, IT project management, digital security policy, food and medicine regulation, and other governmental and private sector consulting. Mr. Lap currently serves as Director, Foundation on Drug Policy and Human Rights, and Director, Drugtext Foundation, and as a Director of various private ventures. Mr. Lap also served as Director of Sales of Apcare B.V., Director of Yalado International B.V., Founder and Director, Calyx Internet B.V. and Calyx Internet Corporation, Professor at the Rechercheschool (Dutch National Police Academy), Head of the Legal and Policy Department of the Netherlands Institute on Alcohol and Other Drugs, and Head of Legal and Policy Department, and Pilot Project of European Monitoring Center on Drugs and Drug Addiction.
Mr. Lap, has an extensive educational background through studies at the Het Amsterdams Lyceum, Colloqium Doctum University of Amsterdam, University of Amsterdam Law School, Open University and University of Liverpool, and speaks fluent Dutch, English, French, and German.
Robert Kane - Chief Operation Officer and Director
Mr. Kane wrote his first business plan in 1996. In 1998, he was hired at Ryan, Beck, and Company, which was bought by the 120-year-old, top ten, financial firm Stifel Nicolaus (NYSE: SF) as a registered representative.
On December 31, 2009, Mr. Kane walked away from the financial markets and started his own firm, Robert Kane Partners, which specializes in business and management planning, investor presentations, and investor relations.
Mr. Kane held the position of Director of Investor Relations for Medical Marijuana, Inc., the first ever publicly traded medical marijuana company. He also held the position of Chief Financial Officer for “Cannabiz Business University.”
Robert Kane's mission is transforming and leading the Medical Cannabis Industry into a viable investment alternative for all types of investors.
Greta Gaines - Product & Marketing Specialist
Greta Gaines is a leading advocate on the reform of cannabinoid law, spending years becoming an authority while serving on the Board of Directors of the National Organization to Reform Marijuana Law (NORML); the Board of the NORML Women's Alliance Foundation (as a Founding Member); and the Advisory Board of Patients Out of Time. Ms. Gaines is well known as an innovator in the use of hemp and developer of cannabinoid-based solutions as a valuable and healing commodity.